Ranitidine as an adjuvant regulates macrophage polarization and activates CTLs through the PI3K-Akt2 signaling pathway
This study provides new evidence for the mechanism by which RAN activates the immune response and is expected to provide a new strategy for the research and development of tumor vaccine adjuvants.PMID:37800555 | DOI:10.1016/j.intimp.2023.109729 (Source: International Immunopharmacology)
Source: International Immunopharmacology - October 6, 2023 Category: Allergy & Immunology Authors: Chenglin Li Shuang Wang Xiaoran Ma Tiantian Wang Ran Lu Xihui Jia Zhe Leng Xiaowen Kong Jinyu Zhang Ling Li Source Type: research
Ranitidine as an adjuvant regulates macrophage polarization and activates CTLs through the PI3K-Akt2 signaling pathway
This study provides new evidence for the mechanism by which RAN activates the immune response and is expected to provide a new strategy for the research and development of tumor vaccine adjuvants.PMID:37800555 | DOI:10.1016/j.intimp.2023.109729 (Source: International Immunopharmacology)
Source: International Immunopharmacology - October 6, 2023 Category: Allergy & Immunology Authors: Chenglin Li Shuang Wang Xiaoran Ma Tiantian Wang Ran Lu Xihui Jia Zhe Leng Xiaowen Kong Jinyu Zhang Ling Li Source Type: research
Ranitidine Use and Incident Cancer in a Multinational Cohort
CONCLUSIONS AND RELEVANCE: In this cohort study, ranitidine use was not associated with an increased risk of cancer compared with the use of other H2RAs. Further research is needed on the long-term association of ranitidine with cancer development.PMID:37725377 | DOI:10.1001/jamanetworkopen.2023.33495 (Source: Cancer Control)
Source: Cancer Control - September 19, 2023 Category: Cancer & Oncology Authors: Seng Chan You Seung In Seo Thomas Falconer Chen Yanover Talita Duarte-Salles Sarah Seager Jose D Posada Nigam H Shah Phung-Anh Nguyen Yeesuk Kim Jason C Hsu Mui Van Zandt Min-Huei Hsu Hang Lak Lee Heejoo Ko Woon Geon Shin Nicole Pratt Rae Woong Park Chris Source Type: research
Pharmacological treatment of gastro-oesophageal reflux in children
CONCLUSIONS: There is very low-certainty evidence about symptom improvements and changes in pH indices for infants. There are no summary data for endoscopic changes. Medications may or may not provide a benefit (based on very low-certainty evidence) for infants whose symptoms remain bothersome, despite nonmedical interventions or parental reassurance. If a medication is required, there is no clear evidence based on summary data for omeprazole, esomeprazole (in neonates), H₂antagonists, and alginates for symptom improvements (very low-certainty evidence). Further studies with longer follow-up are needed. In older children...
Source: Cochrane Database of Systematic Reviews - August 27, 2023 Category: General Medicine Authors: Mark P Tighe Edward Andrews Iona Liddicoat Nadeem A Afzal Andrew Hayen R Mark Beattie Source Type: research
Pharmacological treatment of gastro-oesophageal reflux in children
CONCLUSIONS: There is very low-certainty evidence about symptom improvements and changes in pH indices for infants. There are no summary data for endoscopic changes. Medications may or may not provide a benefit (based on very low-certainty evidence) for infants whose symptoms remain bothersome, despite nonmedical interventions or parental reassurance. If a medication is required, there is no clear evidence based on summary data for omeprazole, esomeprazole (in neonates), H₂antagonists, and alginates for symptom improvements (very low-certainty evidence). Further studies with longer follow-up are needed. In older children...
Source: Cochrane Database of Systematic Reviews - August 27, 2023 Category: General Medicine Authors: Mark P Tighe Edward Andrews Iona Liddicoat Nadeem A Afzal Andrew Hayen R Mark Beattie Source Type: research
Effects of ranitidine and nizatidine on the risk of gastrointestinal cancer
ConclusionOur study, using nationwide retrospective cohort data, did not find evidence suggesting that ranitidine and nizatidine increase the risk of GI cancer. In fact, we observed that the incidence of GI cancer was lower in individuals who used the drugs compared to nonusers. These findings suggest a potential beneficial effect of these drugs on cancer risk, likely attributed to their ability to improve digestive function. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - July 27, 2023 Category: Cancer & Oncology Source Type: research
Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study
CONCLUSIONS: This study demonstrates that the elimination of ranitidine from paclitaxel premedication schedules is non-inferior in the development of HRs of any grade compared to the administration of H2-antagonists.PMID:37477611 | DOI:10.1080/17512433.2023.2238596 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - July 21, 2023 Category: Drugs & Pharmacology Authors: Olalla Montero P érez Javier Martinez Benavides Tania Gonz ález Fernandez Silvia Guerra Prio Roc ío Romero Domínguez Ricard Mes ía Nin Ana Clop és Estela Source Type: research
Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study
CONCLUSIONS: This study demonstrates that the elimination of ranitidine from paclitaxel premedication schedules is non-inferior in the development of HRs of any grade compared to the administration of H2-antagonists.PMID:37477611 | DOI:10.1080/17512433.2023.2238596 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - July 21, 2023 Category: Drugs & Pharmacology Authors: Olalla Montero P érez Javier Martinez Benavides Tania Gonz ález Fernandez Silvia Guerra Prio Roc ío Romero Domínguez Ricard Mes ía Nin Ana Clop és Estela Source Type: research
Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study
CONCLUSIONS: This study demonstrates that the elimination of ranitidine from paclitaxel premedication schedules is non-inferior in the development of HRs of any grade compared to the administration of H2-antagonists.PMID:37477611 | DOI:10.1080/17512433.2023.2238596 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - July 21, 2023 Category: Drugs & Pharmacology Authors: Olalla Montero P érez Javier Martinez Benavides Tania Gonz ález Fernandez Silvia Guerra Prio Roc ío Romero Domínguez Ricard Mes ía Nin Ana Clop és Estela Source Type: research
Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study
CONCLUSIONS: This study demonstrates that the elimination of ranitidine from paclitaxel premedication schedules is non-inferior in the development of HRs of any grade compared to the administration of H2-antagonists.PMID:37477611 | DOI:10.1080/17512433.2023.2238596 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - July 21, 2023 Category: Drugs & Pharmacology Authors: Olalla Montero P érez Javier Martinez Benavides Tania Gonz ález Fernandez Silvia Guerra Prio Roc ío Romero Domínguez Ricard Mes ía Nin Ana Clop és Estela Source Type: research
Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study
CONCLUSIONS: This study demonstrates that the elimination of ranitidine from paclitaxel premedication schedules is non-inferior in the development of HRs of any grade compared to the administration of H2-antagonists.PMID:37477611 | DOI:10.1080/17512433.2023.2238596 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - July 21, 2023 Category: Drugs & Pharmacology Authors: Olalla Montero P érez Javier Martinez Benavides Tania Gonz ález Fernandez Silvia Guerra Prio Roc ío Romero Domínguez Ricard Mes ía Nin Ana Clop és Estela Source Type: research
Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study
CONCLUSIONS: This study demonstrates that the elimination of ranitidine from paclitaxel premedication schedules is non-inferior in the development of HRs of any grade compared to the administration of H2-antagonists.PMID:37477611 | DOI:10.1080/17512433.2023.2238596 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - July 21, 2023 Category: Drugs & Pharmacology Authors: Olalla Montero P érez Javier Martinez Benavides Tania Gonz ález Fernandez Silvia Guerra Prio Roc ío Romero Domínguez Ricard Mes ía Nin Ana Clop és Estela Source Type: research
Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study
CONCLUSIONS: This study demonstrates that the elimination of ranitidine from paclitaxel premedication schedules is non-inferior in the development of HRs of any grade compared to the administration of H2-antagonists.PMID:37477611 | DOI:10.1080/17512433.2023.2238596 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - July 21, 2023 Category: Drugs & Pharmacology Authors: Olalla Montero P érez Javier Martinez Benavides Tania Gonz ález Fernandez Silvia Guerra Prio Roc ío Romero Domínguez Ricard Mes ía Nin Ana Clop és Estela Source Type: research
Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study
CONCLUSIONS: This study demonstrates that the elimination of ranitidine from paclitaxel premedication schedules is non-inferior in the development of HRs of any grade compared to the administration of H2-antagonists.PMID:37477611 | DOI:10.1080/17512433.2023.2238596 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - July 21, 2023 Category: Drugs & Pharmacology Authors: Olalla Montero P érez Javier Martinez Benavides Tania Gonz ález Fernandez Silvia Guerra Prio Roc ío Romero Domínguez Ricard Mes ía Nin Ana Clop és Estela Source Type: research
